AC
HRMY icon

Armistice Capital’s Harmony Biosciences HRMY Stock Holding History

Armistice Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.9M Sell
1,564,000
-60,000
-4% -$1.89M 0.7% 21
2026
Q1 		$45.5M Buy
1,624,000
+1,124,000
+225% +$36.9M 0.81% 19
2025
Q4 		$18.7M Buy
+500,000
New +$16.4M 0.22% 74

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Armistice Capital's HRMY Position: Q2 2026 in Review

Armistice Capital reduced its Harmony Biosciences (HRMY) stake by 3.7% in Q2 2026, selling an estimated $1.89M and leaving 1,564,000 shares worth $56.9M. The position accounts for 0.7% of the portfolio, ranked #21.

Armistice Capital first reported a position in HRMY in Q4 2025 and has held it in 3 quarters since. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Armistice Capital held 1,564,000 shares of Harmony Biosciences worth $56.9M as of Q2 2026.
  • Armistice Capital sold 60,000 Harmony Biosciences shares in Q2 2026, an estimated $1.89M.
  • Harmony Biosciences made up 0.7% of Armistice Capital's portfolio in Q2 2026, its #21 holding.
  • Armistice Capital first reported a position in Harmony Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.